Collegium Pharmaceutical Inc (COLL) Earning Prediction
Collegium Pharmaceutical Inc (COLL) is set to release its earnings performance on 02/26 07:30:00 ET in Pre-Market trading. Consensus forecasts predict a revenue of 208.65M and an earnings per share (EPS) of 2.01 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Earnings Surprise Analysis
COLL Transcript
The earnings call summary and Q&A indicate a positive sentiment. The company reported strong financial performance, with revenue and EBITDA growth, and raised 2025 guidance. Despite increased operational costs, the strategic focus on Jornay PM and share repurchases is promising. The Q&A highlighted stable demand and no significant competitive threats. However, some management responses were vague, slightly tempering enthusiasm. With a market cap of $1.06 billion, the stock is likely to see a positive reaction, between 2% to 8%, given the strong growth and strategic initiatives.
The company reported record high revenue and strong earnings, coupled with optimistic guidance and a raised financial outlook. Despite some uncertainties in strategic execution and M&A specifics, the market is likely to react positively due to robust financial performance, a significant share repurchase program, and strategic growth initiatives. Given the company's small-cap status, these factors are expected to drive a positive stock price movement in the short term.
The earnings call shows strong financial performance with record revenue growth and optimistic guidance, particularly for Jornay PM. The new $150 million share repurchase program and debt repayment plan further enhance investor confidence. Despite increased operating expenses, the company's strategic focus on expanding market reach and awareness, especially among adults, is promising. The Q&A session did not reveal significant risks, and analysts seemed satisfied with management's responses. Considering the company's small-cap status, the positive developments are likely to result in a stock price increase of 2% to 8% over the next two weeks.
The earnings call presents a mixed outlook. While financial performance shows growth, the decline in GAAP net income and EPS, alongside high operating expenses, raises concerns. The positive shareholder return plan and acquisition strategy are offset by competitive pressures and economic uncertainties highlighted in the Q&A. The market cap suggests moderate volatility, but the lack of clear guidance on key strategic initiatives tempers expectations. Overall, the sentiment is neutral given the balanced positives and negatives.
COLL Slides
COLL Report
Frequently Asked Questions
What is the Collegium Pharmaceutical Inc {quarter} Earnings Release Date and Time?
Collegium Pharmaceutical Inc (COLL) is scheduled to release its {quarter} earnings report on Feb 26, 2026, Pre-Market (approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Collegium Pharmaceutical Inc {quarter} Revenue and EPS?
Analysts' consensus predicts 208.65M in revenue and an EPS of 2.01 for Collegium Pharmaceutical Inc's {quarter}.
What Does Intellectia's AI Predict for Collegium Pharmaceutical Inc {quarter} Earnings?
Intellectia's exclusive AI algorithms forecast a {conclusion} for Collegium Pharmaceutical Inc's {quarter} earnings, with a prediction date of Feb 26, 2026. Collegium Pharmaceutical Inc {summary}
How Can I Use This Earnings Prediction to Trade COLL Stock?
Leverage Intellectia's AI forecast to position trades ahead of the Feb 26, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Collegium Pharmaceutical Inc {quarter}?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company's earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They're updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
